Senate Bill Would Address ‘Patent Thicket’ Critics Say Stymies Biosimilars

Drug Industry Daily
A A
A bipartisan group of senators has introduced legislation that would address one of outgoing FDA Commissioner Scott Gottlieb’s pet peeves — the “patent thickets” preventing biosimilars from getting to market.

To View This Article:

Login

Subscribe To Drug Industry Daily